• Publications
  • Influence
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
In patients with familial adenomatous polyposis, six months of twice-daily treatment with 400 mg of celecoxib, a cyclooxygenase-2 inhibitor, leads to a significant reduction in the number of colorectal polyps.
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Its potential to facilitate drug development in seven oncologic settings (lung, lymphoma, breast, prostate, sarcoma, colorectal, and ovary) is addressed and its potential as a surrogate of clinical benefit is addressed.
Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer.
Administration of curcumin to the rats during the initiation and postinitiation stages and throughout the promotion/progression stage increased apoptosis in the colon tumors as compared to colon tumors in the groups receiving AOM and the control diet.
The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
These results provide the first evidence that selective inhibitors of COX-2 are safe and effective for the prevention and regression of adenomas in a mouse model ofAdenomatous polyposis and strongly support ongoing clinical trials in humans with the same syndrome.
I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
I‐SPY 2 (investigation of serial studies to predict your therapeutic response with imaging and molecular analysis 2) is a process targeting the rapid, focused clinical development of paired oncologic
Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol.
The results support previous studies that indole-3-carbinol can prevent mammary carcinogenesis by direct and indirect acting carcinogens and might be a good candidate for chemoprevention of breast cancer in women.
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.
The AACR IEN Task Force recommends focusing on established precancers as the target for new agent development because of the close association between dysplasia and invasive cancer and because a convincing reduction in IEN burden provides patient benefit by reducing cancer risk and/or by decreasing the need for invasive interventions.
Enhancement of experimental colon cancer by genistein.
The results of this investigation emphasize that the biological effects of genistein may be organ specific, inhibiting cancer development in some sites yet showing no effect or an enhancing effect on the tumorigenesis at other sites, such as the colon.
Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats.
While curcumin was highly effective as a chemopreventive agent in the colon model, it was only weakly effective in the mammary model and quercetin caused a dose-dependent enhancement of tumors induced by AOM in the Colon model.
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis
The value of having achieved MRD negativity is substantial in both pediatric and adult patients with ALL and warrants consideration as an early measure of disease response for evaluating new therapies, improving the efficiency of clinical trials, accelerating drug development, and for regulatory approval.